May direct-acting antiviral regimens for chronic hepatitis C virus infections have neuropsychiatric adverse drug reactions? A pilot study conducted in patients receiving sofosbuvir-based regimens in the real-life setting

May direct-acting antiviral regimens for chronic hepatitis C virus infections have... Drugs Ther Perspect (2017) 33:442–447 DOI 10.1007/s40267-017-0422-x ORIGINAL RESEARCH ARTICLE May direct-acting antiviral regimens for chronic hepatitis C virus infections have neuropsychiatric adverse drug reactions? A pilot study conducted in patients receiving sofosbuvir-based regimens in the real-life setting 1 1 1 1 • • • Davide Simeone Anna Maria Spera G. Tosone R. Orlando Published online: 6 July 2017 Springer International Publishing AG 2017 Abstract mood (18.5%), hypochondria (18.5%), initial, middle and Background Until 2011, the standard-of-care therapy for delayed insomnia (14.8% for each type), fear (14.8%), chronic hepatitis C virus (HCV) infections relied on modification of the intellectual sphere (14.8%), and irri- pegylated interferon, whose psychiatric adverse drug tability (14.8%); no suicide attempt or depersonalization/ reactions are well known to treating physicians. From de-realization disorder were reported. No patients with- 2014, direct-acting antivirals (DAAs) with fewer adverse drew from therapy due to psychiatric adverse drug drug reactions and not contraindicated in patients affected reactions. by psychiatric disorders have been used. The aim of the Conclusions This pilot study seems to indicate that the present study is to assess the development of psychiatric occurrence of the psychiatric effects seems to be more effects related to DAA regimens based on http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Drugs & Therapy Perspectives Springer Journals

May direct-acting antiviral regimens for chronic hepatitis C virus infections have neuropsychiatric adverse drug reactions? A pilot study conducted in patients receiving sofosbuvir-based regimens in the real-life setting

Loading next page...
 
/lp/springer_journal/may-direct-acting-antiviral-regimens-for-chronic-hepatitis-c-virus-I6n04bW6Jg
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG
Subject
Pharmacy; Pharmacy; Pharmacotherapy
ISSN
1172-0360
eISSN
1179-1977
D.O.I.
10.1007/s40267-017-0422-x
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial